Results 11 to 20 of about 152,172 (364)
Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/ΔNS2/Δ1313/I1314L and RSV/276 in RSV Seronegative Children. [PDF]
The Journal of Infectious Diseases, 2022 BACKGROUND This United States-based study compared two candidate vaccines: RSV/ΔNS2/Δ1313/I1314L, attenuated by NS2 gene-deletion and temperature-sensitivity mutation in the polymerase gene; and RSV/276, attenuated by M2-2 deletion.
C. Cunningham +22 more
semanticscholar +4 more sources
Immunopathology of RSV: An Updated Review [PDF]
Viruses, 2021 RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding of virus–host interactions and immunity contribute to the lack of biological ...
H. C. Bergeron, R. Tripp
semanticscholar +4 more sources
Socioeconomic Impact of RSV Hospitalization [PDF]
Infectious Diseases and Therapy, 2021 Respiratory syncytial virus (RSV) disease is a significant cause of morbidity and socioeconomic burden worldwide among young children. The majority of RSV-associated lower respiratory tract infections (LRTI) and mortality occurs in developing countries ...
M. Young, L. Smitherman
semanticscholar +4 more sources
A multifaceted approach to RSV vaccination [PDF]
Human Vaccines & Immunotherapeutics, 2018 Respiratory Syncytial Virus (RSV) is the leading cause of pneumonia and bronchiolitis in infants, resulting in significant morbidity and mortality worldwide.
Jorge C. G. Blanco +3 more
doaj +3 more sources
Global molecular diversity of RSV – the “INFORM RSV” study [PDF]
BMC Infectious Diseases, 2020 Abstract Background Respiratory syncytial virus (RSV) is a global cause of severe respiratory morbidity and mortality in infants. While preventive and therapeutic interventions are being developed, including antivirals, vaccines and monoclonal antibodies, little is known about the global molecular epidemiology of RSV.
Langedijk, Annefleur C. +28 more
openaire +6 more sources
An outbreak of RSV infections in a neonatology clinic during the RSV-season [PDF]
BMC Pediatrics, 2021 Abstract Background Respiratory syncytial virus (RSV) is the predominant cause of lower respiratory tract infections (LRTI) in infancy. Preterm infants with bronchopulmonary dysplasia (BPD) are at the highest risk of severe RSV-LRTI.
Liliya Vakrilova +4 more
openaire +3 more sources
, 2021 Respiratory syncytial virus (RSV) hospitalizations disappeared in 2020. Now, with southern hemisphere 2021 winter behind us, RSV has returned. Despite it is difficult to weigh the impact of pandemic mitigation measures on common respiratory virus circulation, it appears that acute respiratory infections in children are returning to their usual ...
Fernando Ferrero +2 more
openaire +1 more source
Journal of Behçet Uz Children's Hospital, 2021 Objective: The risk of severe respiratory syncytial virus (RSV) infection with significant morbidity and mortality is greatest in patients with hemodynamically significant congenital heart disease (hs-CHD). The humanized monoclonal antibody, palivizumab,
Ali Orgun +2 more
doaj +1 more source
Infectious Disease and Therapy, 2023 Introduction Previous studies suggest diagnostic testing characteristics (i.e. variations in clinical specimens and diagnostic tests) can contribute to underestimation of RSV disease burden.
You Li +6 more
semanticscholar +1 more source
Nature Network Boston, 2023 The prolonged persistence at elevated levels of nirsevimab, an RSV-specific monoclonal antibody, likely accounts for the observed protection from severe disease throughout an RSV season, while it does not prevent the induction of a natural immune ...
Deidre Wilkins +10 more
semanticscholar +1 more source